Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks.com  from a “buy” rating to a “hold” score in a research note released to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It focuses on finding and developing little particle medication prospects to treat cancer. The Business‘s products under various stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research experts additionally lately discussed the business. Noble Financial editioned a “buy” score as well as issued a $11.00 rate goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day relocating ordinary cost of $2.90 as well as a two-hundred day relocating ordinary rate of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, covering experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also a negative web margin of 8,294.27%. The company had income of $0.06 million throughout the quarter, compared to the agreement price quote of $0.06 million. Throughout the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will certainly post -1.18 EPS for the present year.

A number of hedge funds have lately dealt shares of ONTX. GSA Capital Allies LLP bought a new placement in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Management LP bought a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a brand-new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP bought a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and various other institutional financiers own 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the recognition and advancement of oncology therapeutics. It concentrates on discovering and also establishing little particle drug candidates to deal with cancer. The company was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a complimentary duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

To find out more regarding research offerings from Zacks Investment Research, visit Zacks.com.

This instantaneous information alert was generated by narrative scientific research technology as well as monetary data from Market in order to offer visitors with the fastest as well as most precise coverage. This tale was assessed by Market’s content team before publication. 



Before you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market keeps an eye on Wall Street’s top-rated and also best carrying out research analysts and the stocks they suggest to their customers daily. Market has actually identified the 5 stocks that top analysts are quietly whispering to their customers to purchase now before the broader market catches on … and Onconova Therapeutics had not been on the checklist.

While Onconova Therapeutics currently has a “Buy” rating among analysts, top-rated analysts think these five stocks are much better acquires.